Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Chi-Heng Wu et al.|Clinical Cancer Research|2019Cited by 40
Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft modelsChi-Heng Wu, Weiyun Z. Ai, Linlin Wang et al.|Blood Advances|2021Cited by 33
Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDACChi-Heng Wu, Weiyun Z. Ai, Taha Rakhshandehroo et al.|Journal of Investigative Dermatology|2020Cited by 21
Abstract 1844: A CD70 antibody-drug conjugate is highly active and induces long term remission in patient-derived xenograft mouse models of cutaneous T cell lymphomaChi-Heng Wu, Weiyun Z. Ai, Chen‐Yen Yang et al.|Cancer Research|2021Cited by 0
Cutaneous T-cell lymphoma patient-derived xenografts retain molecular characteristics across passagesCaroline Snowden, Jaehyuk Choi, Chi-Heng Wu et al.|European Journal of Cancer|2021Cited by 0